Recurrent Melanoma Completed Phase 1 Trials for Cediranib (DB04849)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01131234Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsTreatment